Background: Calprotectin is a promising biomarker for granulocyte activation. It is mainly
| INTRODUCTION
Calprotectin is mainly found in neutrophils, where it accounts for 30% to 40% of the cytosolic protein content. 1 Several inflammatory conditions cause an increase in circulating calprotectin. 2, 3 Calprotectin is, therefore, considered to be an important inflammation marker. 4, 5 The calprotectin molecule is composed of 2 members of the S100 family, S100A8 (MRP8) and S100A9 (MRP14). However, the exact structure of calprotectin is debated. While Johne et al 6 suggest it is a hetero trimer, Pepper et al 7 suggest it is a heterodimer, and Steinbakk et al 8 suggest it is a heterotetramer when calcium is present.
In faeces, elevated calprotectin concentration is used as a marker for inflammatory bowel disease (IBD), including Crohn disease. 9 It has been suggested that serum or plasma calprotectin levels could be used as an important marker for several inflammatory diseases, such as sepsis, 10 acute appendicitis, and rheumatoid arthritis. 7, 11, 12 To be able to develop immunoassays measuring calprotectin reliably, it is important to use a highly purified calprotectin antigen at an early stage, ie, in the immunisation process. The purified antigen must be as similar as possible to the native protein that is to be measured, to avoid assay problems due to differences in antibody reactivity between calibrators, controls, and samples. Presently, calprotectin is mainly used as a faecal biomarker for distinguishing between IBD and irritable bowel syndrome. [13] [14] [15] There are no generally accepted calibrators for calprotectin, for either blood or faeces. Method comparisons show that there are clear calibration differences between F-calprotectin assays from
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This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2018 The Authors. Health Science Reports published by Wiley Periodicals, Inc. different manufacturers. 16 These differences make it difficult to inter- The aim of the present investigation was to develop a method to prepare purified calprotectin, such that it can be used as calibrator and control in immunological calprotectin assays, and for immunisation of hens to raise antibodies. Because of the complex structure of calprotectin, it is difficult to produce recombinant calprotectin in a reproducible way, and there is a risk that the tertiary structure of the recombinant calibrator may be different from the calprotectin present in the patients' samples. 17 We thus chose to purify the calprotectin directly from granulocytes.
| METHODS

| Samples
Informed consent (approval to use excess material in research) was obtained from all blood bank donors. The use of anonymised excess material from the Ullevål Hospital blood bank was approved by the Ethics Committee at Uppsala University (Ups 01-367).
| Extraction
The buffy coats were collected from blood bags (Ullevål Hospital blood bank) after removal of plasma and erythrocytes. 
| Purifying calprotectin antigen
The newly prepared granulocyte extracts were applied to an anion exchange column for purification. The volume of the extract from 4 donors was typically 13 mL. When diluted with purified water to required conductivity, the volume was typically 40 mL. 
| Electrophoresis
| Biuret method
Biuret method was used to measure total protein concentration in the antigen solution. 21 water as the zero standard. As blank sample, 0.9% saline with no preservatives was used. The standards were prepared and measured the same way as described for the sample.
| Yield
The percentage yield was calculated from the concentration of the purified antigen, assigned by Biuret method, and the concentration of the extract measured on BS-380 prior to the purification. 3 | RESULTS
| Stability of the antigen
| Purity of the calprotectin preparations
Buffy coats from 8 (lot 1), 3 (lot 2), and 4 (lot 3) donors were pooled to prepare 3 granulocyte extracts. The 3 extracts were purified with anion-exchange chromatography, where 40 to 50 fractions of the elute were collected from each preparation. The fractions were pooled based on the concentrations measured with the prototype calprotectin immunoassay. The number of fractions pooled varied between each preparation and was determined by the measured concentrations.
The pools were concentrated and washed into saline without preservatives applying the ultracentrifuge filters. The 3 calprotectin preparations were checked for purity by size exclusion chromatography and sodium dodecyl sulphate (SDS) PAGE.
| Size exclusion chromatography
The ultraviolet absorption of the fractions from the size exclusion were compared with the measured calprotectin concentrations determined with the prototype calprotectin immunoassay ( Figure 1) . The calprotectin concentration profile correlated well with the absorbance values. The molecular weight corresponded to oligomers, for the peak at approximately 9.5 mL, and to heterodimers, for the peak at 10.5 mL.
The smaller peak at approximately 15 mL corresponded to the size of monomers.
| Sodium dodecyl sulfate polyacrylamide gel electrophoresis
The electrophoresis gel from the analysis of the 3 antigen batches is shown in Figure 2 . 
| Analysis of the gel by UN-SCAN-IT
The PAGE gel was then analysed by UN-SCAN-IT, transforming the segments 2-1, 4-1, 4-2, and 6-1 in Figure 2 into curves, based on the pixel density.
The pixel analysis by the software UN-SCAN-IT showed that These results suggest that the purified calprotectin antigen solution mostly contains the subunits of the calprotectin molecule, S100A8
and S100A9, and are, therefore, pure. The contamination of undesired proteins was minimal.
| Yield
We then determined the calprotectin concentration and the yield from the extracts.
The total protein concentrations determined by Biuret method spanned from 1079 to 1819 mg/L. On the basis of the results from the electrophoresis analysis and the size exclusion chromatography analysis, we conclude that these are the calprotectin concentrations of the solutions. The percentage yields from the granulocyte extracts varied from 46% to 76.87% in the 3 preparations and the average yield per donor from the 3 purifications spanned from 1.8 to 2.6 mg; see Table 1 .
| Stability of the purified antigen solution
The freeze thaw stability of the antigen was then tested, by measuring the concentration of calprotectin after repeated freeze and thaw cycles. The antigen concentration of the purified antigen solution dropped 14%, from 1566 to 1386 mg/L, after the first freeze and thaw cycle, but seemed to be stabilised at this level through the next 2 cycles. It then dropped, however, to 1251 mg/L after the fourth cycle.
In this 1-test sample, the concentration reduction was altogether of 20% through the 4 freeze and thaw cycles.
To further study the stability of the protein solution, we then tested it by measuring the calprotectin concentration in a HEPES casein buffer over time. The spiked sample measured within 10% from the value at day 0 at all measuring points for 70 days when stored at 44°C, 90 days when stored at 33°C, and for 106 days at 30°C; see 
| DISCUSSION
From a commercial point of view, it is important to establish a purification method with high yields and high grade of purity, to ensure supplies of high demands of antigens for production of calibrators and controls, and for antibodies. For instance, determination of faecal calprotectin levels is a widely used assay to rule out IBD. It is estimated that approximately 11% of the population globally experience 25 The total yield in the purified calprotectin antigen solution varied between 40%
and 80% compared with the measured amount of calprotectin in the extract before the purification.
In addition to the amount, the purity of the antigen solution is important when using the preparations for polyclonal antibody production. Any contamination may induce an immune response that will reduce the specificity of the final assay and should, therefore, be reduced as much as possible. The purity of the prepared antigens was >95%.
The freeze-thaw stability of the purified antigen stored in saline, however, was not what is expected from a calibrator. The pure antigen solution was prepared for immunisation purposes and was not meant to be used as a calibrator as it is. For immunisation purposes, freezethaw stability is not a major issue, as it is stored at −50°C until use.
However, when the antigen is used as calibrators or controls, stability of several months is required when stored at 2°C to 8°C. The sample prepared by spiking HEPES buffer containing casein is a potential solution for a calibrator. When the antigen is spiked into a solution with proteins, the concentration shows little variation within 106 days when stored at 30°C. The stability study was stopped at 106 days because all vials of the samples had been opened; it is expected, however, that the sample is stable for longer than 106 days. From this study design, it is hard to estimate the stability of the antigen in a protein solution when stored at 2°C to 8°C, but it is expected to be substantially longer than the 106 days evaluated for the vials stored at 30°C. To prepare a reference material, the stability of the antigen solution must be investigated further. A next step could be to lyophilisate the solution as an attempt to stabilise the antigen. 
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